1298P RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship
Nakagawa, K., Garon, E., Gao, L., Callies, S., Zimmermann, A., Walgren, R., Visseren-Grul, C., Reck, M.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.1612
Date:
September, 2020
File:
PDF, 130 KB
2020